<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04875299</url>
  </required_header>
  <id_info>
    <org_study_id>ADL-TDM-02</org_study_id>
    <nct_id>NCT04875299</nct_id>
  </id_info>
  <brief_title>Optimal Adalimumab Plasma Concentrations in Ankylosing Spondylitis Patients</brief_title>
  <official_title>Evaluation of the Optimal Concentration Range of Adalimumab for Ankylosing Spondylitis in a Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin First Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuxi No. 2 People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Changzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Hospital of Nantong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qingdao Municipal Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaocheng People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>the first affiliated hospital of Liaoning university of traditional Chinese medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The optimal plasma concentration range of adalimumab in Chinese patients with active&#xD;
      ankylosing spondylitis remains unknown, the aims of this study is to determine the&#xD;
      concentration-effect relationship, and explore the effect of anti-drug antibody or biomarkers&#xD;
      on clinical outcomes in a real-world setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective observational study will include Chinese adult patients with active&#xD;
      ankylosing spondylitis receiving adalimumab treatment. The primary outcome is the mean change&#xD;
      from baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in ASDAS</measure>
    <time_frame>Week 24</time_frame>
    <description>ASDAS will be measured at week 24 and will be compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ASAS20 response</measure>
    <time_frame>Week 2, 4, 8, 12, 24</time_frame>
    <description>ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 20 = 20% improvement (vs. baseline) and an absolute improvement ≥ 10 units on a 0-100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening (defined as a worsening of ≥ 20% and a net worsening of ≥ 10 units) in the remaining domain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASAS40 response</measure>
    <time_frame>Week 2, 4, 8, 12, 24</time_frame>
    <description>ASAS 40 = 40% improvement (vs. baseline) and an absolute improvement ≥ 20 units on a 0-100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening (defined as a worsening of ≥ 20% and a net worsening of ≥ 10 units) in the remaining domain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BASDAI50 response</measure>
    <time_frame>Week 2, 4, 8, 12, 24</time_frame>
    <description>Utilizing a Visual Analog Scale (VAS) of 0-10 (0=none and 10=very severe) subjects answered 6 questions measuring discomfort, pain, fatigue, and morning stiffness. BASDAI 50 = at least 50% improvement (vs. baseline) in BASDAI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASDAS response</measure>
    <time_frame>Week 2, 4, 8, 12, 24</time_frame>
    <description>A decrease in ASDAS from baseline (△ASDAS) ≥ 2.0 or a moderate disease activity achievement (ASDAS &lt; 2.1) with △ASDAS ≥ 1.1 is considered as response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASDAS remission</measure>
    <time_frame>Week 2, 4, 8, 12, 24</time_frame>
    <description>ASDAS &lt; 2.1 at assessment time point is considered as remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety analysis - Occurence of adverse event</measure>
    <time_frame>Week 24</time_frame>
    <description>Safety analysis include occurence of adverse event</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>adalimumab TDM</arm_group_label>
    <description>Patients with active ankylosing spondylitis receiving adalimumab treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>The study is observational</intervention_name>
    <description>The study is observational</description>
    <arm_group_label>adalimumab TDM</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma and DNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This prospective observational study will include Chinese adult patients with active&#xD;
        ankylosing spondylitis receiving adalimumab treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Consent of the patient.&#xD;
&#xD;
          2. Patient who meets the definition of Ankylosing Spondylitis based on the 1984 Modified&#xD;
             New York Criteria, has a diagnosis of active Ankylosing Spondylitis (BASDAI ≥ 4, Back&#xD;
             pain ≥ 4).&#xD;
&#xD;
          3. Patients who have indication of adalimumab.&#xD;
&#xD;
          4. Patients on NSAIDs treatment need to be on a stable dose for at least 4 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        (1) Hepatitis B or tuberculosis patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liyan Miao, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>The Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liyan Miao, Ph.D</last_name>
    <phone>(86) 512 67972858</phone>
    <email>miaolysuzhou@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Liyan Miao, Ph.D</last_name>
      <phone>(86) 512 67972858</phone>
      <email>miaolysuzhou@163.com</email>
    </contact>
    <investigator>
      <last_name>Liyan Miao, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>May 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2021</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Soochow University</investigator_affiliation>
    <investigator_full_name>Miao Liyan</investigator_full_name>
    <investigator_title>vice president</investigator_title>
  </responsible_party>
  <keyword>Ankylosing Spondylitis</keyword>
  <keyword>adalimumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

